A detailed history of Apollon Wealth Management, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Apollon Wealth Management, LLC holds 38,578 shares of NVO stock, worth $5.52 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
38,578
Previous 41,155 6.26%
Holding current value
$5.52 Million
Previous $4.26 Million 16.35%
% of portfolio
0.16%
Previous 0.15%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$102.11 - $135.92 $263,137 - $350,265
-2,577 Reduced 6.26%
38,578 $4.95 Million
Q4 2023

Feb 06, 2024

BUY
$87.78 - $105.45 $2.21 Million - $2.66 Million
25,179 Added 157.61%
41,155 $4.26 Million
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $840,467 - $1.84 Million
9,242 Added 137.24%
15,976 $1.45 Million
Q2 2023

Aug 04, 2023

BUY
$155.98 - $172.65 $43,830 - $48,514
281 Added 4.35%
6,734 $1.09 Million
Q1 2023

May 15, 2023

SELL
$132.34 - $159.14 $37,452 - $45,036
-283 Reduced 4.2%
6,453 $1.03 Million
Q4 2022

Feb 15, 2023

SELL
$102.55 - $135.33 $17,433 - $23,006
-170 Reduced 2.46%
6,736 $911,000
Q3 2022

Nov 08, 2022

BUY
$95.28 - $116.93 $99,091 - $121,607
1,040 Added 17.73%
6,906 $688,000
Q2 2022

Aug 11, 2022

BUY
$103.24 - $121.81 $54,820 - $64,681
531 Added 9.95%
5,866 $654,000
Q1 2022

May 16, 2022

BUY
$93.1 - $112.54 $150,077 - $181,414
1,612 Added 43.3%
5,335 $592,000
Q4 2021

Feb 14, 2022

BUY
$95.88 - $117.08 $356,961 - $435,888
3,723 New
3,723 $417,000
Q1 2021

May 17, 2021

SELL
$67.06 - $75.82 $914,497 - $1.03 Million
-13,637 Closed
0 $0
Q4 2020

Jan 29, 2021

BUY
$63.89 - $73.8 $871,267 - $1.01 Million
13,637 New
13,637 $953,000
Q3 2020

Nov 03, 2020

SELL
$63.69 - $70.22 $1,974 - $2,176
-31 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$58.54 - $67.94 $1,814 - $2,106
31 New
31 $2,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $323B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Apollon Wealth Management, LLC Portfolio

Follow Apollon Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Apollon Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Apollon Wealth Management, LLC with notifications on news.